Rose-The mineral oil was raised as a false flag and excuse to rescind ANCHOR without any considerations to R-I and the damages the slanderous allegation would have on the future stock action of AMRN. As you can see, the damages are real the stock doesn't trade normally: the value of R-I is not priced into the stock because the FDA has already cried foul with R-I placebo. There's no undoing this except R-I approval and label. BB
The FDA tried to explain the changes observed in the mineral oil group, since the magnitude of the changes in several lipid and lipoprotein parameters, as well as biomarkers of inflammation, between baseline and Week 12 in the placebo group wre rather atypical for lipid-lowering trials. However they did not conclude anything
and did not suggest any change for R-IT.
Furthermore, R-IT is about clinical outcome (as PE and SEs) lipid values are TEs only (meanwhile ANCHOR was about lipids).